Related Experiment Video
Updated: May 12, 2026

09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Deep brain stimulation for addiction: why the subthalamic nucleus should be favored
Yann Pelloux1, Christelle Baunez
1Institut de Neurosciences de la Timone, UMR7289 CNRS & Aix-Marseille Université, Campus Santé Timone, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
Current Opinion in Neurobiology
|March 30, 2013
Summary
Deep brain stimulation (DBS) is a novel surgical treatment for addiction. This review argues for the subthalamic nucleus as the optimal target for DBS in addiction treatment.
Area of Science:
- Neuroscience
- Psychiatry
- Neurosurgery
Background:
- Deep brain stimulation (DBS) has emerged as a viable surgical treatment for psychiatric disorders, building on its success in neurological conditions like Parkinson's disease.
- DBS has been established for obsessive-compulsive disorder and treatment-resistant depression, with recent exploration into addiction treatment.
Purpose of the Study:
- To review the theoretical, empirical, and technical evidence supporting the subthalamic nucleus as the primary target for DBS in treating drug addiction.
- To advocate for the subthalamic nucleus over alternative targets for DBS interventions in addiction.
Main Methods:
- Comprehensive review of existing literature on DBS for psychiatric and neurological disorders.
- Analysis of theoretical frameworks, empirical data, and technical considerations for target selection in DBS for addiction.
Main Results:
- The subthalamic nucleus presents a compelling target for DBS in addiction, supported by a convergence of evidence.
- Arguments favor the subthalamic nucleus due to its role in reward pathways and motor control relevant to addiction.
Conclusions:
- The subthalamic nucleus is proposed as the most promising target for deep brain stimulation in the surgical treatment of addiction.
- Further research and clinical trials are warranted to validate the efficacy and safety of targeting the subthalamic nucleus for addiction.

